Naomasa Ioritani

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial

Akihiro Ito, Ichiro Shintaku, Makoto Satoh et al. · Journal of Clinical Oncology · 2013 · 241 citations · Full text

EXPRESSION OF HEPATOCYTE GROWTH FACTOR AND ITS RECEPTOR C-MET IN ACQUIRED RENAL CYSTIC DISEASE ASSOCIATED WITH RENAL CELL CARCINOMA

Ryuichiro Konda, Hiroshi Satō, Fumihiko Hatafuku et al. · The Journal of Urology · 2004 · 50 citations

Psychological distress in Japanese men with localized prostate cancer

Shunichi Namiki, Seiichi Saito, Tatsuo Tochigi et al. · International Journal of Urology · 2007 · 49 citations

Clinical Application of Extracorporeal Shock Wave Lithotripsy using Microexplosions

Masaaki Kuwahara, Koichi Kambe, Seiichi Kurosu et al. · The Journal of Urology · 1987 · 48 citations